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INTRODUCTION
Osteoarthritis (OA) is a common multifactorial, chronic and
progressive joint disease that affects millions of people
globally and has a significant economic impact on welfare
(Arden et al., 2013; Vila, 2017). OA causes pain in the af-
fected joint followed by loss of range of motion and joint
destruction. The changes in OA include cartilage break-
down, the formation of osteophytes, extracellular matrix
degradation, and destabilisation of subchondral bone syn-
thesis with the development of subchondral sclerosis and
cysts. OA has a variable course when exacerbations follow
relative tranquil periods. Two major types of OA are widely
recognised: primary and secondary, or symptomatic and ra-
diographic, accordingly. Despite the sufficient body of
evidence gained on OA, our understanding is far from com-
plete. Previously, the aforementioned features were inter-
preted as the most common changes found in OA, but more
recently a role of inflammation in the development of joint
destruction has been highlighted. Furthermore, a growing
pool of evidence suggests that synovitis (Mainil-Varlet et
al., 2003; Benito et al., 2005; Wenham et al., 2010) is the
prominent etiopathogenic factor in the development of OA.
More recently, Atukorala et al. (2016) suggested that syno-
vitis is a precursor of radiographically evident OA, and
treating synovitis in OA may have a role in reducing pro-
gression of the disease. Conventional radiography methods
are unable to visualise the inflamed and thickened synovial
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The role of inflammation in the development of osteoarthritic joint degeneration is not completely
understood. Recent data suggest that processes that cause and orchestrate inflamed synovial le-
sions may be implicated in the development of the disease. The morphological changes of the
synovium in patients with osteoarthritis (OA), as well as the level of synovial inflammation cau-
tiously graded, in association to the presence of human parvovirus B19 (B19V) infection markers,
were evaluated. Qualitative and quantitative detection of B19V genomic sequence was performed
in OA and rheumatoid arthritis (RA) groups. The expression of CD68, S100 (Ca2+ binding pro-
teins soluble in 100% ammonium sulfate) and B19 VP1/VP2 capsid proteins found in the syno-
vium were investigated by single and double immunolabeling, whereas fine features of
synoviocytes — by electron microscopy. One-third of OA and RA patients demonstrated synovial
expression of B19V antigen, which was confirmed in both types of synoviocytes. The overall ex-
pression of B19V in OA patients was weaker than that found in RA subjects. Positive correlation
between B19V-positive vascular endothelial cells, sublining infiltrating lymphocytes, macro-
phages, and B19V-positive synoviocytes was established. No correlation between synovitis score
indices as well as the expression of S100 and expression of B19V was found. The results sug-
gest that the synovial membrane maintains local joint homeostasis, and that virus mediated syno-
vitis is implicated in the development of OA.
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membrane, whereas use of ultrasonography method has not
yet been verified in large-scale studies of OA (Hayashi et
al., 2011). Therefore, an advanced search for higher effi-
cacy of the synovitis evaluation continues to grow.
The synovial membrane presented by its intimal and
subintimal layers constitutes the innermost part of the joint
envelope. The intimal layer, in turn, contains two cell types
— fibroblast-like (FLS) and macrophage-like synoviocytes
(MLS). In osteoarthritis patients, various synovial inflam-
matory cells and pro-inflammatory agents contribute to sus-
tained joint destruction (de Lange-Brokaar et al., 2012). El-
evated levels of interleukine (IL)-1, tumour necrosis factor
alpha (TNF-), IL-6, IL-7, vascular endothelial growth fac-
tor (VEGF) and numerous other cytokines have been found
in sera, synovial fluid, and synovium of OA patients (Vila,
2017). The innate immune system including its cellular and
humoral defence mechanisms has a significant impact on
the synovium structure and function (Xia et al., 2018). Fur-
thermore, various immune system cells producing S100
Ca2+-binding proteins found in high amounts in the
synovial fluid in the case of OA are believed to promote
further degradation of tissue, eliciting a catabolic effect in
human osteoarthritic chondrocytes (Cecil et al., 2005;
Schelbergen et al., 2012). However, CD68, which is com-
monly used as an inflammation marker recognising
lysosomal proteins is believed to play a crucial role in the
development OA and sustaining chronic inflammation
(Claire et al., 1993; Manferdini et al., 2016). Despite pro-
longed studies, the aetiology of OA exacerbations and in-
flammation drivers remains unknown. However, one of the
possible candidates contributing to the pathogenesis of OA
could be a viral infection, which has been implicated in
other inflammatory arthritides, like rheumatoid arthritis.
Furthermore, it remains controversial whether human
erythrovirus strains related to human parvovirus B19 pro-
voke OA or worsen the clinical presentation of the disease
(Aslan et al., 2008).
B19V is a widespread virus infecting various cellular types
(Cooling et al., 1995; Söderlund-Venermo et al., 2002;
Adamson-Small et al., 2014). Synovial membrane and
joints have been mentioned among the most common B19V
affected tissues in adults (Mauermann et al., 2016), but the
presence of parvovirus B19 DNA in synovial tissue of pa-
tients with joint inflammation does not allow the diagnosis
of parvovirus-induced arthritis (Schmid et al., 2007). The B,
T lymphocytes and antigen-presenting cells (macrophages
and follicular dendritic cells (DC)) have been recognised as
cellular targets and considered to be productively infected
by B19V in affected joints (Takahashi et al., 1998; Lennerz
et al., 2004; Chen et al., 2006). Further demonstration of
the resistance of globoside-negative individuals to infection
with B19V explained the role of this receptor in the infec-
tious process as well as co-receptors in virus binding and in-
ternalisation (Gallinella, 2013). Simultaneously, the inter-
play between the pathogenetic potential of the virus and
tissue constituents has been defined as a significant predic-
tor of outcomes of B19V infection, but unfortunately, is far
from a comprehensive understanding (Kerr, 2000; Stop-
piello et al., 2014). Very few studies related to the
phenotypic changes of synoviocytes inducing an invasive
phenotype in FLS and facilitating cellular migration have
been performed in the case of B19V infection (Ray et al.,
2001; Lu et al., 2006).
The present study aimed at investigating the synovium
changes in osteoarthritis subjects by means of morphology
and virology methods. Also, the Krenn and Morawietz
score, which better reflects the grade of synovitis and in-
creases reproducibility of histopathological data, was evalu-
ated and statistically analysed.
MATERIALS AND METHODS
Patients and controls. OA patients were recruited from
Rîga East University Hospital Clinic “Gaiïezers”. Subjects
who underwent a joint replacement surgery for OA between
January 2016 and September 2018 were enrolled in the
study. The study protocol and the use of the synovial mem-
brane samples were approved by the Ethics Committee of
Rîga Stradiòð University (Decisions of 27.05.2014 and No.
2/08.09.2018), and a written informed consent was obtained
from all patients. The inclusion criteria were primary or pre-
viously established diagnosis of OA established in the given
hospital. All OA subjects fulfilled relevant American Col-
lege of Rheumatology (ACR) criteria for the disease af-
fected joints: hip (Altman et al., 1991) and knee (Altman et
al., 1986).
Fifty-four subjects enrolled in the study (mean age 65,
range 35–85 years, standard deviation (SD) 12.27 years; 19
males and 35 females) had OA confirmed clinically and ra-
diologically and did not reveal any objective and subjective
evidences of any other inflammatory disease apart from
OA. Seven subjects with rheumatoid arthritis as a primary
joint disease (mean age 65, range 35–67 years, SD 9.1
years; one male and six females) constituted a comparison
group.
Molecular virology. Initially, the subjects were screened
for B19V-related IgG and IgM antibodies. The synovial tis-
sue total DNA was obtained using standard phenol-chloro-
form extraction. Concentration of extracted DNA was mea-
sured spectrophotometrically (Nanodrop ND-1000
Spectrophotometer, Thermo Fisher Scientific, Waltham,
MA, USA) and the quality of DNA tested by detecting the
presence of the -globin gene sequence using polymerase
chain reaction (PCR) (Naciute et al., 2016) (C1000 Touch
Thermal Cycler, Biorad, Hercules, CA, USA).
For quantitative detection of B19V genomic sequence real-
time PCR (qPCR) was performed in both the OA and RA
groups. A commercially available qPCR kit (B19V
Real–TM Quant, Sacace Biotechnologies Srl, Italy), which
included the standards, the positive and the negative con-
trols, was used to detect the B19V VP1 genomic region.
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Estimation of synovitis using Krenn score. To better
grade synovitis and obtain reproducible histopathological
data, the Krenn and Morawietz score was used (Krenn et
al., 2006). Cellular hyperplasia of intimal layer, cellular
density of subintimal layer and inflammatory infiltration
were semiquantitatively estimated: 0 – absent, 1 – mild, 2 –
moderate, and 3 – strong. Additionally, we estimated the
presence and density of congested synovial capillaries
scored in the subintimal layer as follows: 0 – few, 1 – small
numbers of profiles, which are loosely packed, 2 – moderate
numbers, which are more densely packed, and 3 – high
numbers of profiles revealing dense spatial distribution. The
sum obtained provided the synovitis score, which was inter-
preted as follows: 0–1, no synovitis; 2–4, low-grade synovi-
tis; and 5–9, high-grade synovitis.
Immunohistochemistry. Immunohistochemistry (IHC) ei-
ther as single or double immunolabelling was performed
manually using sections collected on SuperFrost Plus slides
(Gerhard Menzel GmbH, Germany). For single antigen de-
tection, sections were deparaffinised, and endogenous per-
oxidase activity was blocked with 0.1% H2O2 in methanol.
Heat-induced antigen retrieval was accomplished with the
sections placed in 10 mmol/l sodium citrate buffer pH 6.0
for 30 min in a vapour lock. Non-specific binding was
blocked with 1% bovine serum albumin/5% normal goat se-
rum in phosphate buffered saline. Immunohistochemistry
was performed manually using incubation at 4 °C overnight
with the following primary antibodies: monoclonal anti-
B19V antibody reacting with B19 VP1/VP2 capsid proteins
(Novocastra, Leica Biosystems, Newcastle, UK, clone
R92F6, 1 : 20); and monoclonal mouse anti-human S100
(Cell Marque, Rocklin, CA, USA, clone 4C4.9, 1 : 100).
Amplification of primary antibody and visualisation of reac-
tion products was performed applying the HiDef Detection
Horseradish Peroxidase (HRP) Polymer system (Cell-
Marque, Rocklin, CA, USA) or Novolink Plymer Detection
System and diaminobenzidine tetrahydrochloride (DAB)
substrate kit (UltraMarque HRP Detection system). Finally,
the sections were washed with distilled water, and counter-
stained with Mayer’s hematoxylin.
For double labelling confirming the presence of nuclear
B19V and cytoplasmic CD68 localisation, simultaneously
the EnVision™ G|2 Doublestain kit (DakoCytomation,
Glostrup, Denmark 1 : 50) was used. Sections were incu-
bated for 5 min with Dual Endogenous Enzyme Block,
buffer washed, incubated with anti-B19V antibody for 10
min, Polymer/HRP, and DAB+ Working Solution for up to
one hour at room temperature 20–25 °C, rinsed; then incu-
bated with Doublestain Block, thereafter with anti-CD68
antibody for 10 min, Rabbit/Mouse LINK, rinsed, incubated
with Polymer/AP for 10 min, rinsed, and incubated with
Permanent Red Working Solution for 20 minutes. Then the
slides were rinsed in a fresh distilled water for five minutes,
counterstained with Mayer’s hematoxylin, washed with wa-
ter, mounted, and covered with coverslips. Cells that were
labelled with the above-mentioned antibodies and displayed
brown (both brown and red for doublestaining) reaction
products were considered immunopositive. Sections from
cases with known antibody positivity were used as positive
controls. IHC controls that included substitution of the pri-
mary antibodies with tris(hydroxymethyl)aminomethane
(TRIS) solution (pH = 7.4) were used as negative controls.
The sections were photographed under a Leitz DMRB mi-
croscope using a digital camera DC 300F.
For immunofluorescence, sections were counterstained with
4',6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Sci-
entific, Invitrogen, UK, 1 : 3000) and embedded in Prolong
Gold with DAPI (Thermo Fisher Scientific, Invitrogen,
UK). Tissue autofluorescence was suppressed by 0.2% Su-
dan Black B solution (Sigma Aldrich, St. Louis, MO) bef-
ore cover slipping. The sections were examined with a Leitz
DMRB (Leitz, Germany) using a digital camera DC 300F
and Nikon confocal microscope Eclipse Ti-E (Nikon, Ja-
pan).
Electron microscopy. Synovial tissue samples were fixed
in 2.5% glutaraldehyde in 0.1 M phosphate buffer at pH 7.4,
postfixed in 1% OsO4, dehydrated in a series of graded
ethanols and acetone, and embedded in epoxy resin. Ultra-
thin 60-nm-thick fine sections were cut with an LKB ultra-
microtome, collected on copper grids, double stained with
uranyl acetate and lead citrate, and examined with a JEOL
1011 transmission electron microscope (JEOL JEM 1011,
Japan) at accelerating voltage 80–100 kV and at magnifica-
tion 4000–30 000×.
Statistical data analysis. Statistical data analysis was per-
formed in order to estimate the immunohistochemistry re-
sults. A Kolmogorov-Smirnov normality test was used to
detect any differences between samples. The quantitative
data were expressed as means ± standard deviation and as
medians with interquartile range (IQR), whereas categorical
parameters were expressed as frequencies and percentages.
Two values were considered to be statistically significantly
different in cases when the confidence level of the differ-
ence between them was greater than 95% (p < 0.05). The
SPSS version 24.0 software was used for statistical analysis.
RESULTS
Polymerase chain reaction. In the arthritic subjects, the
B19V VP1 genomic sequence was detected in 6 of 58
(10.3%) synovial membrane tissue samples, in 3 out of 51
(5.8%) OA and in 3 out of 7 (42.9%) RA patients, respec-
tively. Furthermore, the B19V VP1 genomic sequence was
identified in a RA case with high-grade synovitis.
Conventional light microscopy. Conventional light mi-
croscopy of the OA lesioned synovium samples demon-
strated hyperplasia of synovial lining, sublining fibrosis,
and stromal vascularisation (Fig. 1A). Macrophage and
lymphocyte infiltration in the synovium was common as
well (Fig. 1B). Some macrophages were clustered and
formed multinucleated giant cells. A Kolmogorov-Smirnov
test was performed on all statistical data. The test revealed
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that the Krenn score did not follow a normal distribution
(D44 = 0.176, p = 0.002), and the blood vessel index did not
follow a normal distribution (D43 = 0.218, p < 0.005). Con-
gested synovial capillaries presented with the median value
1.0 IQR (2.0).
Estimation of synovitis using the Krenn score revealed great
range — from 0 up to 5 with median value 2.0, IQR (2.0).
Low-grade synovitis was found in the majority of cases (10
out of 44 (22.72%). 5 (11.36%). OA subjects revealed the
absence of synovial inflammation, whereas 4 (9.75%) pre-
sented with moderate synovitis.
Immunohistochemistry. Eleven of 39 (28.2%) OA and two
of 7 (28.6%) RA subjects showed positive synovial staining
of B19V antigen. Double labelling using anti-B19V and
anti-CD68 antibodies showed expression of viral proteins in
both synovial cellular types — macrophages and FLS (Fig.
2A and insert C). The overall expression of B19V in OA
patients was either weak or mild, but one patient demon-
strated a strong decoration of the synovium with the anti-
B19V antibody. Virological analysis of this patient con-
firmed acute viremia. Also, positive B19V expression was
strong in red bone marrow cells, mostly erythroid and blood
platelet cell lines, vascular endothelium and muscular cells.
Furthermore, a positive correlation between B19V-positive
vascular endothelial cells and erythroid cells in the red bone
marrow (r = 0.846, p < 0.004), and between B19V-positive
vascular endothelial cells and B19V-positive synoviocytes
(r = 0.579, p = 0.001) was found. In contrast, no correlation
between synovitis score indices reflecting synovial inflam-
mation and expression of B19V was found. Mild to strong
synovial expression of B19V was demonstrated in RA pa-
tients. A strong positive correlation (r = 0.744, p < 0.001)
and r = 0.696, p < 0.0001) was established in the synovium
of OA subjects when B19V-positive synoviocytes and sub-
Fig. 1. Histopathology of the OA lesioned synovium. (A) Synovium with hyperplasia of the lining layer (black arrows) showing congested capillaries (black
dashed arrows), and occasional inflammatory cells (red arrow), ×200. (B) The synovial area in a case of chronic synovitis is manifested with the lining hyper-
plasia and lymphoid and plasma cell infiltration (black arrows), ×200.
Fig. 2. (A) Double immunohistochemical staining using two monoclonal antibodies targeting CD68 (red arrow) and B19V (brown arrow) in the synovium of
OA subject. Image depicts lysosomal proteins within synovial macrophages (red arrow) and nuclei of vascular endothelial cells, FLS and some macrophages
stained for B19V (brown arrow), ×400. (B) S100 synovial immunoreactivity revealed mostly perivasculary (black arrows), ×250. Insert (C):
immunofluorescence demonstrating nuclei of synoviocytes and sublining stroma cells stained with DAPI (blue) and VP1/VP2 capsid proteins (green).
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lining infiltrating lymphocytes and macrophages were esti-
mated, respectively (Fig. 3A and 3B).
Unequal synovial expression of S100 family proteins was
noticed in the samples studied — S100 positivity was found
in 14 patients of 61 (23%). The expression was mostly
moderate, and anti-S100 decoration displayed both diffuse
and local distribution pattern. The synovial lining macro-
phages and follicular dendritic cells displayed S100 expres-
sion (Fig. 2B). No statistically significant correlation be-
tween synovial expression of parvovirus B19 viral proteins
and expression of S100 was found.
Transmission electron microscopy. Transmission electron
microscopy examination of the lining layer demonstrated ir-
regularly shaped cells revealing a large number of exten-
sions of the cell membrane (Fig. 4A). The plasma mem-
brane of MLS possessed numerous fine extensions
characteristic of macrophages. The cytoplasm of MLS re-
vealed conspicuous cisternae of Golgi apparatus, phago-
somes, large vacuoles, and small vesicles localised around
the nucleus. FLS revealed prominent cytoplasmic exten-
sions that often extended into the surface of the synovial
lining. Invaginations along the plasma membrane were fre-
quent. FLS displayed mostly a phenotype evidencing exten-
sive synthetic activity — abundant rough endoplasmic re-
ticulum and the Golgi apparatus; polymerised, greatly
varying collagen microfibrils occurred nearby (Fig. 4.B).
Inflammatory cells (occasional lymphocytes, clustered lym-
phocytes, and plasma cells) were observed in the case of
synovitis.
DISCUSSION
Osteoarthritis is a common joint disease affecting the entire
joint and particularly soft tissues. Usually, the disease mani-
fests in OA patients in their sixties. However, undisputed
evidence suggesting that OA may develop in younger peo-
ple was provided, thus highlighting contribution of other
factors than mechanical wear to the disease (Sulzbacher,
2012). Investigation of the synovitis in OA damage has re-
Fig. 3. (A) Correlation between
B19V-positive synoviocytes and sub-
lining infiltrating lymphocytes. (B)
Correlation between B19V-positive
synoviocytes and sublining macro-
phages.
Fig. 4. Synovial membranes pathological histology findings on transmission electron microscopy. (A) Fine structure of the synoviocytes revealed using trans-
mission electron microscopy, ×10 000. (B) Great variation in both by fine structure and diameter of collagen microfibrils (black arrows) revealed using trans-
mission electron microscopy within the sublining layer, ×15 000.
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ceived much attention of the scientific community during
the last decade (Sellam et al., 2010; Mathiessen et al.,
2017). Furthermore, viruses were recognised among inflam-
mation inducers and factors contributing to OA relapsing
nature (Rollín et al., 2007). Previous studies have demon-
strated that B19V, hepatitis B and C as well as HIV are
among the most common causal agents of virus-mediated
arthritis worldwide (Marks et al., 2016). Furthermore, de-
spite the fact that most virus-mediated arthritides are
self-limiting, these often require careful consideration of
virological, clinical, laboratory and other features to guide
physicians in making diagnostic and treatment decisions.
B19V DNA prevalence in synovial tissue of RA patients
has been shown in several studies, including cohort studies
investigating the presence of B19V infection markers
(genomic sequences and virus-specific antibodies) in asso-
ciation with the level of cytokines and RA clinical activity
and aggressiveness (Naciute et al., 2016). Very few studies
have been reporting on the influence of B19V in OA pa-
tients (Rollín et al., 2007; Aslan et al., 2008). Difficulties
arising around the excellent diagnosis of parvovirus-in-
duced arthritis have been reported previously (Schmid et
al., 2007), even in cases confirmed by the presence of par-
vovirus B19V DNA in synovial tissue. Our results show
that 16 of 54 (29.6%) OA patients are infected with B19V;
none of them had an exacerbation of the disease. One of the
subjects enrolled in the study presented with viremia and a
high number of infected synovial cells confirmed immuno-
histochemically. The presence of B19V infection markers
was detected in both OA and RA groups of patients, and
was more heavily expressed in RA subjects (42.9%), thus
highlighting the necessity of further studies addressed to
larger cohorts of Latvian population. Sensitivity and speci-
ficity of PCR and IHC data is a commonly debatable issue.
Molecular virology methods are sufficiently used when
quick screening and diagnostics is requested, whereas IHC
labelling is used to access more information on the number
and cell types contributing to either degenerative or inflam-
matory process characteristic of the arthritic lesion.
In contrast, the level of C-reactive protein (CRP) was only
slightly elevated, and the Krenn score index was low. In this
context, the results are in accordance with previously re-
ported data suggesting the persistence of B19V in subjects
without clinically evident complains characteristic of arthri-
tis (Söderlund et al., 1997; Watanabe et al., 2018). Further-
more, B19V-related arthralgia is usually self-limited but
may persist for several months or recur over months to
years (Bultmann et al., 2003; von Landenberg et al.,
2007).
According to the proposal made by Gallinella (2013), out-
comes of B19V infection depend on the interaction between
the pathogenetic potential of the virus, its adaptation to dif-
ferent cellular environments, and the physiological and im-
mune status of the infected individuals. To better under-
stand the contribution of synovial inflammation in general,
and changes of synoviocytes in particular, to the clinical
manifestations of OA and exacerbations of the disease, we
have performed immunohistochemistry and electron mi-
croscopy investigations. The results of double staining
immunohistochemistry suggest B19V persistence and dem-
onstrate that the B19V sequence is present in both types of
synoviocytes — FLS and MLS. Furthermore, it has been
generally considered that FLS bear cytological characteris-
tics of the nonpermissive cells, which are not able to sustain
the viral replication. Simultaneously, the significance of the
differentiation stage and physiological state of cells essen-
tial for the virus to complete a productive cycle has been
highlighted in recent investigations (Gallinella, 2017). Our
immunohistochemistry results demonstrate that viral capsid
proteins are found in the synovium of OA patients, and
more specifically — FLS. This is consistent with previous
results (Magro et al., 2004), which show the presence of
B19V in the skin fibroblasts of scleroderma patients fol-
lowed by the unregulated release of TNF-. Furthermore,
B19V NS-1 protein activates proinflammatory growth fac-
tor – TNF- and IL-6 encoding genes (Fu Y et al., 2002;
Mitchell et al., 2002). FLS in the heavily populating intimal
layer may either develop from migratory cells bearing pre-
cursor features or arrive from the circulation or residential
cell pool located in the synovium and bone (Tolboom et al.,
2002; Mor et al., 2005; Steenvoorden et al., 2007). Viral
exposure may cause the phenotypic changes and aggressive-
ness of FLS accompanied by increased production of matrix
metalloproteinases (MMP) and other extracellular matrix
degrading molecules further contributing to joint destruc-
tion (Bartok et al., 2011). Furthermore, activity of IL-6,
IL-1 mRNA and matrix metalloproteinase 9 (MMP9) in-
creases in cells treated with B19 VP1 protein (Tzang et al.,
2009). The presence of other receptors (as exemplified by
studies with erythropoetin receptor) and co-receptors of
globoside seems to be essential for B19V to complete the
replication cycle (Chen et al., 2010). Pathogenic pathways
of B19V-associated with autoimmunity include cross-reac-
tion of anti-B19V antibodies with human proteins and
B19V-induced apoptosis, which results in presentation of
self-antigens to T lymphocytes, and the VP1 region-related
phospholipase activity (Kerr et al., 2016). This, at least
partly, explains a broad spectrum of cells and tissues in-
fected by B19V (Gallinella, 2017; Munakata et al., 2018),
but intimate details of the synovial cellular affection in case
of OA are far from being complete, and similarities of
B19V exposure in RA and OA patients cannot be excluded
(Naciute et al., 2017).
Ca2+-binding protein S100 was found in abundance in rheu-
matic disease, stimulating inflammatory cell motility and
cytokine release (Donato et al., 2013). Nakashima et al.
(2012) showed elevation of S100A12 (calgranulin C) in the
human OA chondrocytes, whereas S100A8 (calgranulin A)
and A9 (calgranulin B) within synovium, chondrocytes and
bone (Zreiqatet et al., 2007). Furthermore, S100 was sug-
gested as a trigger of catabolic biochemical reactions in OA
chondrocytes (Schelbergen et al., 2012). In RA subjects,
S100 overexpression was found in the synovial membrane
stimulating a local release of matrix metalloproteinases
(Senolt et al., 2006). In our study, we did not find signifi-
cant correlations between B19V and S100 expression.
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We recognise limitations of our study, including a small
number of OA cases, semiquantitative measures of immu-
noexpression, and the lack of clinical data regarding the
first-onset manifestations, exacerbations and the appropriate
laboratory analyses. However, we believe that the study
showed a significant association between B19V DNA de-
tection and IHC staining in synovial tissue, providing new
insights into biology and pathogenesis of OA.
In conclusion, our findings suggest that the synovial mem-
brane, an essential organ maintaining homeostasis of the
joint cavity, is implicated in the development of OA. Fur-
ther studies deciphering peculiarities of the structure and
function of the inflamed synovium and role of the infectious
agents in virus-mediated arthritis are needed.
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SINOVÎTS OSTEOARTRÎTA PACIENTIEM: MORFOLOÌISKIE UN VIROLOÌISKIE PIERÂDÎJUMI TÂ IETEKMEI UZ SLIMÎBAS
ATTÎSTÎBU
Iekaisuma nozîme locîtavu deìenerâcijas attîstîbâ osteoartrîta (OA) gadîjumâ nav pilnîbâ izzinâta. Jaunâkie dati liecina, ka procesi, kas
veicina iekaisuma izraisîtus bojâjumus sinoviâlâs membrânas audos, var bût saistîti ar slimîbas attîstîbu. Pçtîjumâ tika analizçtas
morfoloìiskâs izmaiòas sinoviâlâs membrânas audos OA un reimatoîdâ artrîta (RA) pacientiem, kâ arî izvçrtçta to korelâcija ar
imûnhistoíîmiski noteiktu cilvçka parvovîrusa B19 (B19V) antigçnu klâtbûtni sinoviâlo audu paraugos. CD68, S100 un B19 VP1/VP2
antigçnu imûnekspresija sinovija audos tika pçtîta, izmantojot rutînas un dubultâs iezîmçðanas imûnhistoíîmijas metodes. OA (28.2%) un
RA (28.6%) pacientiem tika novçrota B19V antigçnu ekspresija sinoviâlajâ membrânâ. Pçtîjumâ tika novçrota pozitîva korelâcija starp
B19V pozitîvajâm endoteliâlajâm ðûnâm un sinoviâlâs membrânas stromâlâs daïas B19V pozitîvajiem limfocîtiem, makrofâgiem, kâ arî
sinoviocîtiem. Korelâcija starp sinoviâlo audu iekaisuma pakâpi un S100 ekspresiju, kâ arî starp B19V ekspresiju un iekaisuma pakâpi
netika atrasta. Pçtîjuma rezultâti liecina, ka sinoviâlâ membrâna uztur locîtavas homeostâzi, un B19V infekcijas izraisîts sinoviâlo audu
iekaisums ir saistîts ar artrîta attîstîbu.
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